Effect of JWH-250, JWH-073 and their interaction on "tetrad", sensorimotor, neurological and neurochemical responses in mice.
Andrea Ossato, Isabella Canazza, Claudio Trapella, Fabrizio Vincenzi, Maria Antonietta De Luca, Claudia Rimondo, Katia Varani, Pier Andrea Borea, Giovanni Serpelloni, Matteo Marti
Progress in Neuro-Psychopharmacology and Biological Psychiatry June 3, 2016 DOI: 10.1016/j.pnpbp.2016.01.007 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical in vitro and in vivo pharmacological study Peer reviewed |
|---|---|
| Population | Male CD-1 mice |
| Interventions | JWH-250 JWH-073 AM 251 |
| Keywords | Jwh-018 Jwh-073 Jwh-250 Microdialysis δ9-THC |
| Key points | JWH-250 and JWH-073 each produced hypothermia, antinociception, catalepsy, reduced motor activity, impaired sensorimotor responses, seizures, and other neurological effects in mice, and dose-dependently stimulated nucleus accumbens dopamine release; all effects were prevented by the CB1 antagonist AM 251. Co-administration of otherwise ineffective doses of both compounds impaired visual sensorimotor responses, improved mechanical pain threshold, and stimulated mesolimbic dopamine transmission, which the authors interpret as evidence of potentially synergistic action that may increase the compounds' dangerousness and abuse potential. |
Abstract
JWH-250 and JWH-073 are two synthetic cannabinoid agonists with nanomolar affinity at CB1 and CB2 receptors. They are illegally marketed within "herbal blend" for theirs psychoactive effects greater than those produced by Cannabis. Recently, we analyzed an "herbal" preparation containing a mixture of both JWH-250 and JWH-073. The present study was aimed at investigating the in vitro and in vivo pharmacological activity of JWH-250 and JWH-073 in male CD-1 mice. In vitro competition binding experiments performed on mouse and human CB1 and CB2 receptors revealed a nanomolar affinity and potency of the JWH-250 and JWH-073. In vivo studies showed that JWH-250 and JWH-073, administered separately, induced a marked hypothermia, increased pain threshold to both noxious mechanical and thermal stimuli, caused catalepsy, reduced motor activity, impaired sensorimotor responses (visual, acoustic and tactile), caused seizures, myoclonia, hyperreflexia and promote aggressiveness in mice. Moreover, microdialysis study in freely moving mice showed that systemic administration of JWH-250 and JWH-073 stimulated dopamine release in the nucleus accumbens in a dose-dependent manner. Behavioral, neurological and neurochemical effects were fully prevented by the selective CB1 receptor antagonist/inverse agonist AM 251. Co-administration of ineffective doses of JWH-250 and JWH-073 impaired visual sensorimotor responses, improved mechanical pain threshold and stimulated mesolimbic DA transmission in mice, living unchanged all other behavioral and physiological parameters. For the first time the present study demonstrates the overall pharmacological effects induced by the administration of JWH-250 and JWH-073 in mice and it reveals their potentially synergistic action suggesting that co-administration of different synthetic cannabinoids may potentiate the detrimental effects of individual compounds increasing their dangerousness and abuse potential.
Citations in the library
Cited by 14
- Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Frontiers in Neuroscience April 19, 2016
- Sex and Gender Differences in the Effects of Novel Psychoactive Substances. Brain Sciences September 3, 2020
- Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset CNS & Neurological Disorders - Drug Targets April 17, 2017
- New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat. Experimental Neurology November 1, 2021
- Acute Effects of the Psychedelic Phenethylamine 25I-NBOMe in C57BL/6J Male Mice. International Journal of Molecular Sciences March 20, 2025
and 9 more in the library
Cites 9
- Beyond THC: The New Generation of Cannabinoid Designer Drugs Frontiers in Behavioral Neuroscience 2011
- “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report Human Psychopharmacology: Clinical and Experimental July 1, 2013
- Psychoactive drug or mystical incense? Overview of the online available information on Spice products International Journal of Culture and Mental Health December 1, 2009
- Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice. Neuropharmacology August 2015
- Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. Journal of Pharmacology and Experimental Therapeutics September 2013
and 4 more in the library